Skip to main content
SpringerLink
Log in
Book cover

Drug Management of Prostate Cancer pp 147–151Cite as

Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer

  • Chapter
  • First Online:

  • 1213 Accesses

Abstract

Increased understanding of the biology of advanced prostate cancer has yielded multiple targets that are worthy of evaluation. Multiple signaling pathways appear to play a role in the maintenance and progression of the malignant phenotype. These pathways, such as PI3 kinase/Akt pathway, the mTOR pathway, the Hsp90 pathway, and the insulin-like growth factor 1 pathway, are currently being investigated in clinical trials. Other fundamental processes such as histone deacetylation are also involved in prostate cancer progression. Testing agents targeting these pathways will provide crucial information regarding whether inhibition will yield clinical benefit for prostate cancer patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23(3):455–60.

    Article  PubMed  CAS  Google Scholar 

  2. Gross M, Higano C, Pantuck A, et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142.

    Article  PubMed  Google Scholar 

  3. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24(50):7465–74.

    Article  PubMed  CAS  Google Scholar 

  4. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8(4):1168–71.

    PubMed  Google Scholar 

  5. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64(15):5232–6.

    Article  PubMed  CAS  Google Scholar 

  6. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142(11):4795–805.

    Article  PubMed  CAS  Google Scholar 

  7. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275(32):24500–5.

    Article  PubMed  CAS  Google Scholar 

  8. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5(7):433–7.

    Article  PubMed  CAS  Google Scholar 

  9. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81.

    Article  PubMed  CAS  Google Scholar 

  10. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10(6):594–601.

    Article  PubMed  CAS  Google Scholar 

  11. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62(21):6141–5.

    PubMed  CAS  Google Scholar 

  12. Lerut E, Roskams T, Goossens E, et al. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC). J Clin Oncol (Meeting Abstracts) 2005;23(16_suppl):3071.

    Google Scholar 

  13. Efstathiou E, Tsavachidou D, Wen S, Troncoso P, Mills GB, Logothetis CJ. Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with Temsirolimus with or without androgen ablation. J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):5071.

    Google Scholar 

  14. O’Reilly KE, Rojo F, She Q-B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500–8.

    Article  PubMed  Google Scholar 

  15. George DA, Armstrong AJ, Creel P, et al. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer. Proceedings of the Genitourinary Cancers Symposium 2008: Abstract 181.

    Google Scholar 

  16. Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):5069.

    Google Scholar 

  17. Smaletz O, Kelly WK, Horse-Grant D, et al. Epothilone B analogue (BMS-247550) with estramustine phosphate in patients with progressive castrate-metastatic prostate cancer. Proc Am Soc Clin Oncol 2002;21:732.

    Google Scholar 

  18. Heath EI, Hillman D, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):15553.

    Google Scholar 

  19. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279(5350):563–6.

    Article  PubMed  CAS  Google Scholar 

  20. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11(8):3065–74.

    Article  PubMed  CAS  Google Scholar 

  21. Krueckl SL, Sikes RA, Edlund NM, et al. increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64(23):8620–9.

    Article  PubMed  CAS  Google Scholar 

  22. Kiyama S, Morrison K, Zellweger T, et al. castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63(13):3575–84.

    PubMed  CAS  Google Scholar 

  23. Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerre F, Housset M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995;36(3):259–62.

    Article  PubMed  CAS  Google Scholar 

  24. Koutsilieris M, Mitsiades CS, Bogdanos J, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10(13):4398–405.

    Article  PubMed  CAS  Google Scholar 

  25. Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 2008;101(4):436–9.

    Article  PubMed  CAS  Google Scholar 

  26. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13(18):5549s–55s.

    Article  PubMed  CAS  Google Scholar 

  27. Lai M-T, Yang C-C, Lin T-Y, Tsai F-J, Chen W-C. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 2008;26(2):182–9.

    Article  PubMed  CAS  Google Scholar 

  28. Zhang Z, Stanfield J, Frenkel E, Kabbani W, Hsieh J-T. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. Urology 2007;70(2):396–401.

    Article  PubMed  Google Scholar 

  29. Parker C, Molife R, Karavasilis V, et al. Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):15507.

    Google Scholar 

  30. Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. Clin Prostate Cancer 2005;4(2):83–5.

    Google Scholar 

    Google Scholar 

  31. Marrocco DL, Tilley WD, Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007;6(1):51–60.

    Article  PubMed  CAS  Google Scholar 

  32. Bradley DA, Dunn R, Rathkopf D, et al. Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. Proceedings of the Genitourinary Cancers Symposium 2008: Abstract 211.

    Google Scholar 

  33. Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 2006;4(2):113–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Jonathan Rosenberg

Authors
  1. Jonathan Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Rosenberg .

Editor information

Editors and Affiliations

  1. Medical Oncology Branch, NIH National Cancer Institute, Rockville Pike 9000, Bethesda, 20892, Maryland, USA

    William D. Figg

  2. Medical Oncology Branch, NIH National Cancer Institute, Rockville Pike 9000, Bethesda, 20892, Maryland, USA

    Cindy H. Chau

  3. School of Medicine, Dept. Urology, University of California, San Francisco, Divisadero Street 1600, San Francisco, 94115, California, USA

    Eric J. Small

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rosenberg, J. (2010). Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer. In: Figg, W., Chau, C., Small, E. (eds) Drug Management of Prostate Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-829-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-829-4_13

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-831-7

  • Online ISBN: 978-1-60327-829-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation